Alchemist A151216 - Genetic Testing For Patients with Resectable or Resected Lung Cancer
Alchemist E4512 - Testing The Addition Of The Drug Crizotinib After Surgery To Remove ALK-Positive Non-Small Cell Lung Cancer
Alchemist A081801 - Testing The Addition Of A Type Of Drug Called Immunotherapy To The Usual Chemotherapy Treatment For Non-Small Cell Lung Cancer
A011801 - This trial studies how well trastuzumab emtanzine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. Giving T-DMI and tucatinib together may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
MA.39 Tailor RT (Radiation Oncology) - A Randomized Trial of Regional Radiotherapy in BIOMARKER Low Risk Node Positive Breast Cancer
NRG BR004 - Testing The Drug Atezolizumab Or Placebo With Usual Therapy In First-Line HER2-Positive Metastatic Breast Cancer
AFT 25 - COMET - Comparing An Operation To Monitoring, With Or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
Emerge 402 - Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca.
A071801 - This study is being done to answer the following question: does fractionated (multiple treatment sessions) radiosurgery delivered to the surgical cavity in the brain (the part of the brain where the brain metastasis was resected) decrease the risk of tumor recurring in the surgical cavity compared to single fraction (single treatment session) radiosurgery?
BRAT (Radiation Oncology) - The purpose of the Prostate BRAchyTherapy (BRAT) Registry is to measure clinical outcomes of patients treated with Brachytherapy at Lexington Medical Center (LMC).
VERACITY - V3011102 Randomized, Active-Controlled, Phase 3 Study of VERU111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients who have Failed Prior Treatment with at Least One Androgen Receptor Targeting Agent.